14 recruiting, 11 not yet recruiting, 9 completed, 6 active not recruiting. 39 Phase 2, 20 Phase 1, 4 Phase 3.
Follow Temozolomide (TMZ): new trials by email Literature Review of Temozolomide (TMZ) trials Research Report on Temozolomide (TMZ)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT) - Glioblastoma, High-Grade Glioma (WHO III-IV) | Phase 1 / Phase 2 | Not yet recruiting | Sabine Mueller, MD, PhD | 97 | 2027-06-01 | 2026-09-15 |
| Trial of Temozolomide in BAP1 Mutated Patients With Advanced or Metastatic Cutaneous Melanoma Temozolomide (TMZ) - Cutaneous Melanoma | Phase 2 | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 28 | 2027-06-01 | 2026-09-08 |
| IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas IDH1-vac, IS-vac, Temozolomide (TMZ) - Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Not yet recruiting | German Cancer Research Center | 216 | 2027-02-01 | 2026-10-22 |
| Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma Tris-CAR-T cell injection, Ommaya reservoir implantation, Temozolomide (TMZ) - Newly Diagnosed Glioblastoma, IDH-wildtype | Phase 2 / Phase 3 | Not yet recruiting | Beijing Tiantan Hospital | 60 | 2026-10-15 | 2026-10-14 |
| TRINITY TRIAL; Trial Of PRRT Plus CAPTEM Vs CAPTEM Alone In Well Differentiated GEP NETS Capecitabine, Temozolomide (TMZ), Lutetium Lu 177 Dotatate - Gastroenteropancreatic Neuroendocrine Tumors | Phase 3 | Not yet recruiting | Tata Memorial Hospital | 123 | 2026-10-11 | 2026-11-02 |
| A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers AL58805, AL3818, Temozolomide (TMZ) - Endometrial Neoplasms, Ovarian Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | Advenchen Pharmaceuticals, LLC. | 138 | 2026-09-01 | 2026-09-10 |
| Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy BreakVax, Ipilimumab 2.5 mg, Pembrolizumab - Glioblastoma (GBM) | Phase 1 / Phase 2 | Not yet recruiting | BreakBio Corp | 10 | 2026-09-01 | 2026-08-19 |
| Levetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma Levetiracetam Extended-Release Granules, Temozolomide (TMZ), Radiotherapy - Glioblastoma | Phase 2 | Not yet recruiting | Tianjin Medical University General Hospital | 140 | 2026-09-01 | 2026-08-11 |
| Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease Liothyronine (L-T3), Bevacizumab, Irinotecan - Medulloblastoma, Medulloblastoma, Childhood | Phase 1 / Phase 2 | Recruiting | Sabine Mueller, MD, PhD | 69 | 2026-08-21 | 2026-09-28 |
| Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer Intensity-Modulated Radiation Therapy, Hypofractionated Radiation Therapy, Temozolomide (TMZ) - Advanced Glioblastoma | Phase 2 / Phase 3 | Not yet recruiting | Alliance for Clinical Trials in Oncology | 422 | 2026-06-10 | 2026-05-26 |
| Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII silevertinib in combination with temozolomide, temozolomide (TMZ) - Glioblastoma (GBM), Newly Diagnosed Glioblastoma | Phase 2 | Recruiting | Black Diamond Therapeutics, Inc. | 162 | 2026-05-05 | 2026-11-02 |
| Focused Ultrasound Blood-Brain Barrier Opening in Pontine Diffuse Midline Glioma to Enhance Temozolomide Therapy: Pilot Feasibility Study (FIDES) Focused Ultrasound (FUS) Blood-Brain Barrier Opening, Temozolomide (TMZ) - Diffuse Midline Glioma, H3 K27-Altered | Phase 1 / Phase 2 | Not yet recruiting | UMC Utrecht | 20 | 2026-05-01 | 2026-05-01 |
| Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma Personalized Dendritic Cell Vaccine ZSNeo-DC1.1, Temozolomide (TMZ) - Glioblastoma | Phase 2 | Not yet recruiting | ZSky Biotech Inc | 78 | 2026-01-09 | 2026-01-26 |
| Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors Tarlatamab, Temozolomide (TMZ) - Glioma, CNS Tumor, Adult | Phase 1 / Phase 2 | Recruiting | Centre Leon Berard | 70 | 2025-11-04 | 2026-09-14 |
| PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors PEEL-224, Vincristine, Temozolomide (TMZ) - Refractory Solid Tumors, Relapsed Solid Tumors | Phase 1 / Phase 2 | Recruiting | Theodore Laetsch | 59 | 2025-03-23 | 2026-10-06 |
| Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma Vorasidenib, Temozolomide (TMZ) - IDH1-mutant Glioma, IDH2-mutant Glioma | Phase 1 / Phase 2 | Active not recruiting | Institut de Recherches Internationales Servier | 51 | 2025-01-22 | 2026-07-08 |
| DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma DB107-RRV, DB107-FC, Radiation Therapy (RT) - High Grade Glioma, MGMT-Unmethylated Glioblastoma | Phase 1 / Phase 2 | Recruiting | University of California, San Francisco | 70 | 2025-01-08 | 2026-03-11 |
| A Multi-Arm, Platform Trial For Relapsed Neuroblastoma Bevacizumab, Dinutuximab beta, Irinotecan (drug) - Relapsed Neuroblastoma | Phase 1 / Phase 2 | Recruiting | University of Birmingham | 160 | 2024-11-11 | 2026-01-12 |
| A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma Ivoximab 20 mg/kg, ivgtt, Q4W, Temozolomide (TMZ) - Relapsed/Refractory Glioma | Phase 1 / Phase 2 | Recruiting | The First Affiliated Hospital of Zhengzhou University | 29 | 2024-10-10 | 2026-05-20 |
| Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant Ribociclib, Everolimus, Temozolomide (TMZ) - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Phase 2 | Recruiting | Nationwide Children's Hospital | 120 | 2024-08-22 | 2026-05-29 |
Showing 20 of 44. Sign in to see all of them.
Glioblastoma (20) · Glioma (12) · Brain Neoplasms (6) · Astrocytoma (4) · Melanoma (4) · Recurrence (4) · Central Nervous System Neoplasms (2) · Medulloblastoma (2) · Neuroblastoma (2) · Ovarian Neoplasms (2) · Breast Neoplasms (1) · Central Nervous System Diseases (1) · Diffuse Intrinsic Pontine Glioma (1) · Endometrial Neoplasms (1) · Ependymoma (1)
Memorial Sloan Kettering Cancer Center (2) · Sabine Mueller, MD, PhD (2) · University of California, San Francisco (2) · Advenchen Pharmaceuticals, LLC. (1) · Alliance for Clinical Trials in Oncology (1) · Assistance Publique Hopitaux De Marseille (1) · AstraZeneca (1) · Australian & New Zealand Children's Haematology/Oncology Group (1) · BPGbio (1) · Beijing Tiantan Hospital (1) · Black Diamond Therapeutics, Inc. (1) · BreakBio Corp (1) · Cantex Pharmaceuticals (1) · Case Comprehensive Cancer Center (1) · Centre Francois Baclesse (1)
United States (24) · China (8) · Germany (7) · France (6) · Australia (5) · Austria (5) · Canada (5) · Spain (5) · United Kingdom (5) · Netherlands (4) · Belgium (3) · Italy (3) · Sweden (3) · Czechia (2) · Denmark (2)
Sabine Mueller, MD, PhD (2) · Amedeo A Azizi, MD (1) · Andreas Peyrl, MD (1) · Andrew B Lassman, MD (1) · Ashley Ghiaseddin, MD (1) · Carlos K Matsuoka, MD (1) · Daniel Morgenstern, Dr (1) · David Peereboom, MD (1) · David Ziegler, Prof (1) · Jacquelyn Crane, MD (1) · Jiayi Huang, MD (1) · Jing Wu, M.D. (1) · Judy Chen (1)
PMID 29412784, PMID 12675312, PMID 13680158, PMID 15173079, PMID 16200343, PMID 16530701, PMID 16786120, PMID 16899365, PMID 17664336, PMID 17705175, PMID 18509186, PMID 19221744, PMID 20167817, PMID 20838435, PMID 21147753, PMID 21150307, PMID 21327941, PMID 22665268, PMID 23243055, PMID 25856312, PMID 26311731, PMID 26545842, PMID 27006176, PMID 27230974, PMID 27247755, PMID 27782828, PMID 28439777, PMID 29763623, PMID 30397180, PMID 30771200, PMID 30819765, PMID 31419298, PMID 33123732, PMID 33713320, PMID 33754151, PMID 33921457, PMID 34185076, PMID 34261630, PMID 3470008, PMID 34795007, PMID 35124175, PMID 35332121, PMID 35344040, PMID 35412366, PMID 35567713, PMID 36090479, PMID 36291912, PMID 36362482, PMID 36648215, PMID 36689692
2023 (2), 2018 (1), 2025 (1)